Condition (MeSH)
Transposition of Great Vessels
ClinicalTrials.gov lists 49 trials for Transposition of Great Vessels or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
43 of the 49 trials are tagged with Transposition of Great Vessels itself; the rest are tagged with a narrower condition beneath it.
When did Transposition of Great Vessels trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 4 |
| 2016 | 1 |
| 2015 | 2 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Transposition of Great Vessels trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 16 |
| Observational | 22 |
How many Transposition of Great Vessels trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 9 |
| Active, not recruiting | 3 |
| Completed | 30 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Transposition of Great Vessels trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
Which drugs are being tested for Transposition of Great Vessels? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nitric Oxide | 1 |
| EPOETIN ALFA | 1 |
| DEXMEDETOMIDINE | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| CELSIOR® group | 1 |
| N Acetylcysteine | 1 |
| Eplereone | 1 |
| Non intervention | 1 |
| Saint-Thomas group | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Transposition of Great Vessels trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiopulmonary insufficiency requiring ECMO | 4 | 1 |
| Cardiac arrest requiring CPR and medications | 3 | 1 |
| Seizures | 3 | 1 |
| Need for dialysis | 2 | 1 |
| Bleeding requiring surgical re-exploration | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Transposition of Great Vessels? (117)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Health-related quality of life in patients with a systemic right ventricle: the QUALISYSTEMIC study. | European journal of cardiovascular nursing | 2025 | Yes |
| Quality of Life in Adults With Transposition of the Great Arteries With a Systemic Right or Left Ventricle. | The Canadian journal of cardiology | 2025 | Yes |
| Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE. | European journal of heart failure | 2023 | Yes |
| Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease. | Journal of the American College of Cardiology | 2023 | Yes |
| The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. | ESC heart failure | 2022 | Yes |
Showing 5 of 117 publications.
Prevalence (54)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Transposition of the great arteries | Prevalence at birth | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Transposition of the great arteries | Prevalence at birth | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Transposition of the great arteries | Prevalence at birth | 1-5 / 10 000 | United Kingdom | GB | Unspecified |
| Transposition of the great arteries | Prevalence at birth | 1-5 / 10 000 | United States | US | Exact |
| Transposition of the great arteries | Prevalence at birth | 1-5 / 10 000 | United States | US | Unspecified |
Showing 5 of 54 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Transposition of the great arteries | 216675 | Exact | Orphadata Science knowledge files, Product 1 |
| Transposition of the great arteries | 216675 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.